New chemical entities are largely insoluble, which creates a significant challenge when formulating new drugs; but scientists have recognised the potential of metal organic frameworks (MOFs) as alternative delivery mechanisms for such drugs.
List view / Grid view
European Pharmaceutical Review
Filter the results
The drug daratumumab has been approved for treatment of multiple myeloma, demonstrating increased efficacy when used in combination with other drugs.
According to a new report, blockchain technology in the healthcare market size is set to increase exponentially.
The articles in this In-Depth Focus delve into the effectiveness of the FMD and why it is necessary as well as how drug manufacturers need to become innovative in their processes.
This In-Depth Focus investigates anticancer nanomedicine developments and the future of MALDI imaging for pharmaceutical formulation research.
This In-Depth Focus highlights why bio-fluorescent particle detection is an effective method for enumerating present microbes and discusses ICH Q10 knowledge management; presenting five tips for improving your company’s knowledge management.
This issue includes an investigation into the potential for continuous production lines in biopharma, information on new guidance released by China on their regulatory processes and an assessment of the FMD to improve the drug supply chain. Also within the issue are articles on nanomedicine development, monoclonal antibodies and pharmaceutical…
An MHRA consultation is due to end on 31 August, with public comments on AQbD principles closing soon.
The DHSC has confirmed that several pharmaceutical industry bodies have agreed to NDAs regarding plans for a no-deal Brexit.
The NICE and NHS have announced their draft recommendations for the prescribed use of cannabis-based treatments.
2019 has seen a marked increase of antibody biosimilar product approvals in the first half of the year, according to a report.
Pharma contract placement was found to increase by 250 percent compared to last year, according to figures from a recruitment firm.
The US Federal Trade Commission is investigating whether Johnson and Johnson violated antitrust laws with its medication, Remicade.